
Fennec - A Sound Case For Long-Term Growth?
Shares of Fennec Pharmaceuticals Inc. (FENC) touched a new 52-week high of $8.26 yesterday, driven by the company's optimized sales strategy for its lead product, Pedmark, and its successful expansion into additional markets. Pedmark is the first and …